Drugs / 20vPCV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06838000 | Feb 2025 → Dec 2026 expected | pneumococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT07348692 Comparator | Jan 2026 → Jun 2027 expected | — | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT07247188 Comparator | Jan 2026 → Jan 2027 expected | sickle cell disease | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 20vPCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07348692 ↗ |
| Known as | Prevnar 20 | “20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20)” NCT06838000 ↗ |
| Modality | Vaccine | “20-valent pneumococcal conjugate vaccine” NCT06838000 ↗ |
| Route | Intramuscular | “3 intramuscular injections of pneumococcal vaccine” NCT06838000 ↗ |